PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Threshold Pharma to Progress Pancreatic Cancer Drug to Phase 3

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival. These findings spooked investors in the biotechnology company and the shares dropped as much as a third. However, some analysts believe that these investors have overreacted, because overall survival was not the primary endpoint of the Phase 2 studies.

Th-302 is an investigational hypoxia-targeted drug for patients with advanced pancreatic cancer. The Phase 2 findings indicated that patients treated with Gemzar (Eli Lilly’s chemotherapy drug gemcitabine) alone had a median overall survival of 6.9 months, compared with 9.2 months for patients treated with 340mg of TH-302 plus gemcitabine. This increase is not seen as statistically significant.

TH-302 also continues to demonstrate a safety profile consistent with what was previously reported at the 2012 annual meeting of the American Association for Cancer Research.

“We are pleased with the overall consistency of results from this study demonstrating activity of TH-302 and, as a consequence, a randomized Phase 3 trial of TH-302 in patients with advanced first-line pancreatic cancer is planned to be initiated together with our partner Merck KGaA. We are grateful to the clinical investigators and patients who have participated in our studies of TH-302 and would like to acknowledge their important contributions to advancing the development of novel therapies for pancreatic cancer.”

Barry Selick, Ph.D., Chief Executive Officer of Threshold.

Threshold Pharma’s TH-302 is also being tested in a further 11 clinical trials at the moment. If the FDA approves it in conjunction with Gemzar for pancreatic cancer, TH-302 will join the current crowded market, which includes Peregrine Pharmaceutical’s bavituximab and Celgene’s Abraxane.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026